Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Mary Ann, Sellers"'
Autor:
Angelique E. Boutzoukas, Rachel Olson, Mary Ann Sellers, Gwenyth Fischer, Chi D. Hornik, Omar Alibrahim, Kelechi Iheagwara, Kamal Abulebda, Andora L. Bass, Katherine Irby, Anjali Subbaswamy, Elizabeth E. Zivick, Jill Sweney, Anne G. Stormorken, Erin E. Barker, Riad Lutfi, Michael C. McCrory, John M. Costello, Kate G. Ackerman, Jennifer C. Munoz Pareja, J. Michael Dean, Nael Abdelsamad, Daniel F. Hanley, W. Andrew Mould, Karen Lane, Mary Stroud, Bryan J. Feger, Rachel G. Greenberg, P. Brian Smith, Daniel K. Benjamin, Christoph P. Hornik, Kanecia O. Zimmerman, Mara L. Becker
Publikováno v:
Contemporary Clinical Trials. 125:107067
Timely trial start-up is a key determinant of trial success; however, delays during start-up are common and costly. Moreover, data on start-up metrics in pediatric clinical trials are sparse. To expedite trial start-up, the Trial Innovation Network p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d545b2e05c18921644ebcfb6890538c3
https://doi.org/10.1016/j.cct.2022.107067
https://doi.org/10.1016/j.cct.2022.107067
Autor:
Jarosław D. Kasprzak, Arnold I. Levinson, Vic Hasselblad, Warren J. Cantor, Kurt Huber, Michael Aschermann, Jose Lopez-Sendon, Lauren Glenn, P. Gabriel Steg, Paul W. Armstrong, Béla Merkely, Christopher E. Buller, Marco Valgimigli, Rod Stables, Renato D. Lopes, Steven L. Zelenkofske, Toomas Marandi, Peep Laanmets, Mauricio G. Cohen, Peter Sinnaeve, Thomas J. Povsic, Jan H. Cornel, Viliam Fridrich, Marilyn Borgman, João Morais, Mary Ann Sellers, Richard C. Becker, Zhen Huang, Roxana Mehran, John H. Alexander, A. Michael Lincoff, Christoph Bode, Victor Guetta
BACKGROUND REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. We tested the hypothesis that near complete inhibiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1000c49359a083088e2c932f666833
Autor:
Beena S Cracknell, Eric L. Eisenstein, Peter Sandercock, Robert M. Califf, Christopher B. Granger, Mary Ann Sellers, Elizabeth D. Reid, Rory Collins, Yuriy Shakhov, Michael L. Terrin, Oscar Podesta, Rafael Diaz
Publikováno v:
Clinical Trials. 5:75-84
Background Over the past decade, annual funding for biomedical research has more than doubled while new molecular entity approvals have declined by one third. Objective To assess the value of practices commonly employed in the conduct of large-scale
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412851fedd9f57d02eed1e45d6368955
https://doi.org/10.1177/1740774507087551
https://doi.org/10.1177/1740774507087551
Autor:
Marc A. Pfeffer, Aldo P. Maggioni, John J.V. McMurray, Jean-Lucien Rouleau, Marc Henis, Eric Neuhart, Frans Van de Werf, Susan Edwards, Paul Gallo, Alain Leizorovicz, Mary Ann Sellers, Robert M. Califf, Eric J. Velazquez
Publikováno v:
American Heart Journal. 140:727-750
Background Survivors of acute myocardial infarction (MI) complicated by heart failure and/or resulting in left ventricular dysfunction are at heightened risk for subsequent death and major nonfatal cardiovascular events. Inhibition of the renin-angio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690a852769337d07b1c5a5ae0581b049
https://doi.org/10.1067/mhj.2000.108832
https://doi.org/10.1067/mhj.2000.108832
Autor:
John J.V. McMurray, Christopher B. Granger, Marc A. Pfeffer, Rodney Sparapani, Gunilla Ohlin, Lynn Warner Stevenson, Eric L. Michelson, Jean L. Rouleau, Mary Ann Sellers, Salim Yusuf, James B. Young, J. Kuch, Bradley A. Bart, Aldo P. Maggioni, Peter Held, Robert M. Califf, Georg Ertl, Karl Swedberg
Publikováno v:
American Heart Journal. 139:609-617
Background May patients with congestive heart failure do not receive the benefits of angiotensin-converting enzyme (ACE) inhibitors because of intolerance. We sought to determine the tolerability of an angiotensin II receptor blocker, candesartan cil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acc1d85b2a399f1873576213225de95a
https://doi.org/10.1016/s0002-8703(00)90037-1
https://doi.org/10.1016/s0002-8703(00)90037-1
Autor:
Franco Malcolm O. Cobelli, Christopher B. Granger, Georg B. Ertl, Jerzy B. Kuch, Aldo P. Maggioni, John P. McMurray, Jean-Lucien P. Rouleau, Lynn Warner P. Stevenson, Karl P. Swedberg, James P. Young, Salim P. Yusuf, Robert M. Califf, Bradley A. Bart, Peter A. Held, Eric L. Michelson, Mary Ann Sellers, Gunilla Ann Ohlin, Rodney Ann Sparapani
Publikováno v:
American Heart Journal. 139:0609-0617
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4304535e29794dd8487a3e3cf5c91dc8
https://doi.org/10.1067/mhj.2000.103541
https://doi.org/10.1067/mhj.2000.103541
Autor:
Karen S. Pieper, Mark F. Newman, Jeffrey D. Leimberger, Melanie C. Wright, F. Van de Werf, Mark Stafford-Smith, Marc A. Pfeffer, Jeffrey M. Taekman, Rafael Diaz, Barbara Phillips-Bute, Robert M. Califf, Eric J. Velazquez, Mary Ann Sellers
Publikováno v:
Qualitysafety in health care. 19(5)
Recognition of learning curves in medical skill acquisition has enhanced patient safety through improved training techniques. Clinical trials research has not been similarly scrutinised. The VALsartan In Acute myocardial iNfarcTion, a large multinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5276cd104ce0916364728d742e3e44e
https://pubmed.ncbi.nlm.nih.gov/20702441
https://pubmed.ncbi.nlm.nih.gov/20702441
Autor:
Jasmina I. Radeva, Kevin P. Weinfurt, Mary Ann Sellers, Leah E. Masselink, Marc A. Pfeffer, Robert M. Califf, Eric J. Velazquez, Jennifer S. Allsbrook, Shelby D. Reed, John J.V. McMurray, Kevin A. Schulman
Publikováno v:
American heart journal. 150(2)
Background In a multinational clinical trial, valsartan was statistically not inferior to captopril in reducing mortality and cardiovascular morbidity after myocardial infarction (MI) in patients with signs of heart failure and/or left ventricular dy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb71c923f7ee4bbd6a534726f5ead512
https://pubmed.ncbi.nlm.nih.gov/16086938
https://pubmed.ncbi.nlm.nih.gov/16086938
Autor:
Marc A, Pfeffer, John J V, McMurray, Eric J, Velazquez, Jean-Lucien, Rouleau, Lars, Køber, Aldo P, Maggioni, Scott D, Solomon, Karl, Swedberg, Frans, Van de Werf, Harvey, White, Jeffrey D, Leimberger, Marc, Henis, Susan, Edwards, Steven, Zelenkofske, Mary Ann, Sellers, Robert M, Califf, A, Trapani
Publikováno v:
The New England journal of medicine. 349(20)
background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1cfbd5aaf4407380f9fe349878add6e
https://pubmed.ncbi.nlm.nih.gov/15257858
https://pubmed.ncbi.nlm.nih.gov/15257858
Autor:
Jean-Lucien Rouleau, Harvey D. White, Paul Gallo, Mary Ann Sellers, Aldo P. Maggioni, Eric J. Velazquez, Jeffrey D. Leimberger, Marc A. Pfeffer, Karl Swedberg, Frans Van de Werf, Robert M. Califf, Susan Edwards, Lars Køber, John J.V. McMurray, Marc Henis
Publikováno v:
European journal of heart failure. 5(4)
Background: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2a391773ecb7fd1dc99bb84b58b908
https://pubmed.ncbi.nlm.nih.gov/12921816
https://pubmed.ncbi.nlm.nih.gov/12921816